Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Ramelteon in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT00671190
First received: May 1, 2008
Last updated: February 27, 2012
Last verified: February 2012
  Purpose

The purpose of this study is to determine the phase-advance in circadian rhythms in healthy adults subjects taking ramelteon, once daily (QD).


Condition Intervention Phase
Sleep Disorder
Drug: Ramelteon
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Phase-Shifting Effects of Repeated Daily Dosing of Ramelteon in Healthy Subjects

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Dim Light Melatonin Secretion Offset Time. [ Time Frame: Days 1, 2, 3, and 4 or Final Visit. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Dim-Light Melatonin Onset (DLMOn) time. [ Time Frame: Days 1, 2, 3, and 4 or Final Visit. ] [ Designated as safety issue: No ]

Enrollment: 75
Study Start Date: March 2005
Study Completion Date: May 2005
Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ramelteon 1 mg QD Drug: Ramelteon
Ramelteon 1 mg, tablets, orally once daily for up to 5 days
Other Names:
  • Rozerem™
  • TAK-375
Experimental: Ramelteon 2 mg QD Drug: Ramelteon
Ramelteon 2 mg, tablets, orally once daily for up to 5 days
Other Names:
  • Rozerem™
  • TAK-375
Experimental: Ramelteon 4 mg QD Drug: Ramelteon
Ramelteon 4 mg, tablets, orally once daily for up to 5 days
Other Names:
  • Rozerem™
  • TAK-375
Experimental: Ramelteon 8 mg QD Drug: Ramelteon
Ramelteon 8 mg, tablets, orally once daily for up to 5 days
Other Names:
  • Rozerem™
  • TAK-375
Placebo Comparator: Placebo QD Drug: Placebo
Ramelteon placebo-matching tablets, orally once daily for up to 5 days

Detailed Description:

Circadian rhythms are the innate daily fluctuation of physiologic or behavior functions, included sleep-wake states, generally tied to the 24-hour daily dark-light cycle. Circadian Rhythm Sleep Disorders share a common chronophysiologic basis in which the major feature is a misalignment between the patient's sleep pattern and the sleep pattern that is desired or regarded as the societal norm.

Circadian Rhythm Sleep Disorders affect a sizable portion of the United States population, representing a significant underserved need. It has been estimated that 7% of all adolescents suffer from Delayed Sleep Phase Syndrome. Approximately 1% of all middle-aged people have Advanced Sleep Phase Syndrome. There are 21 million people who are shift workers and between 5% to 20% of these workers develop severe symptoms of Shift Work Sleep Disorder soon after starting shift work. Time Zone Change (Jet Lag) Syndrome can affect millions of travelers each year. Most symptoms are a result of sleep deprivation.

Current treatment of these disorders include behavioral therapy, light therapy and use of hypnotics and stimulants. Melatonin has also been used with mixed results.

The effects of melatonin on circadian phase depend on the time at which it is administered, and are generally opposite those of light. Specifically, melatonin given in the evening results in an advance of the circadian system to an earlier hour ("phase advance"). While melatonin appears to be useful in the treatment of sleep disruption in the blind, the phase shifting ability of native melatonin is much less than that of light, limiting its utility in the treatment of circadian dysfunction in sighted individuals.

Ramelteon is under global development as a sleep-promoting agent. Ramelteon demonstrates affinity and selectivity for human melatonin-1 or melatonin-2 receptors. Ramelteon also demonstrates full agonist activity relative to melatonin in cells expressing human melatonin-1 or melatonin-2 receptors.

The purpose of this study is to determine whether ramelteon given over multiple days can produce a phase advance in circadian rhythms as measured in salivary melatonin levels in dim-light conditions. Participation in this study is anticipated to be about 4 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria

  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration
  • Habitual bedtime is between 10:00 p.m. and 1:00 a.m.
  • Body mass index between 18 and 30, inclusive.
  • Medial subjective sleep latency of less than 30 minutes and a median subjective total sleep time of greater than 6.5 but less than 9 hours.

Exclusion Criteria

  • Known hypersensitivity to ramelteon or related compounds, including melatonin, and melatonin related compounds.
  • Previously participated in a study involving ramelteon.
  • Participated in any other investigational study and/or taken any investigational drug within 30 days or five half-lives prior to the first dose of single-blind study medication, whichever is longer.
  • Sleep schedule changes required by employment (eg, shift worker) within three months prior to the administration of single-blind study medication.
  • Flown across greater than three time zones within 21 days prior to or during screening.
  • Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to the administration of single-blind study medication.
  • Ever had a history of seizures, sleep apnea, restless leg syndrome, periodic limb movement syndrome, chronic obstructive pulmonary disease, schizophrenia, bipolar disorder, mental retardation, or cognitive disorder.
  • History of primary sleep disorders as determined by the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised within the past 6 months.
  • History of psychiatric disorder (including anxiety or depression) within the past 12 months.
  • History of alcohol abuse within the past 12 months, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition Revised, or regularly consumes more than 14 alcoholic drinks per week, or consumes any alcoholic drinks 2 hours prior to bedtime.
  • History of drug abuse within the past 12 months.
  • Current neurological, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, hematologic, or metabolic disease.
  • Apnea hypopnea index (per hour of sleep) greater than 10.
  • Periodic leg movement syndrome with arousal index (per hour of sleep) greater than 10 as seen on the polysomnography screening night.
  • Positive urine drug screen.
  • Smokes greater than 3 cigarettes per day or uses tobacco products during nightly awakenings.
  • Reports high caffeine consumption (greater than 500 mg daily).
  • Any clinically important abnormal finding as determined by a medical history, physical examination, electrocardiogram, or clinical laboratory tests, as determined by the investigator.
  • Positive hepatitis panel including anti-hepatitis.
  • Unwilling to remain in the sleep laboratory in dim-light conditions for 5 days and nights or fully cooperate with site personnel.
  • Any additional condition(s) that in the Investigator's opinion would:

    • affect sleep/wake function
    • prohibit the subject from completing the study
    • not be in the best interest of the subject.
  • Is required to take or continues taking any disallowed medication, prescription medication, herbal treatment or over-the counter medication, including:

    • Anxiolytics
    • Central nervous system active drugs (including herbal)
    • Antipsychotics
    • Narcotic analgesics
    • Antidepressants
    • Beta blockers
    • Anticonvulsants
    • St. John's Wort
    • Sedating H1 antihistamines
    • Kava-kava
    • Systemic steroids
    • Ginkgo-biloba
    • Respiratory stimulants
    • Over the counter and prescription stimulants
    • Decongestants
    • Over-the-counter and prescription diet aids
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00671190

Locations
United States, Arkansas
Hot Springs, Arkansas, United States
United States, California
Los Angeles, California, United States
San Diego, California, United States
United States, Florida
Miami, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Macon, Georgia, United States
United States, Indiana
Danville, Indiana, United States
United States, Kansas
Overland Park, Kansas, United States
United States, Louisiana
Metairie, Louisiana, United States
United States, Maryland
Chevy Chase, Maryland, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, Ohio
Dublin, Ohio, United States
United States, South Carolina
Columbia, South Carolina, United States
Sponsors and Collaborators
Takeda
Investigators
Study Director: VP Clinical Science Takeda
  More Information

Additional Information:
Publications:
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT00671190     History of Changes
Other Study ID Numbers: 01-02-TL-375-018, U1111-1114-8304
Study First Received: May 1, 2008
Last Updated: February 27, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
Sleep Disorder
Circadian Rhythm Sleep Disorder
Drug Therapy

Additional relevant MeSH terms:
Parasomnias
Sleep Disorders
Mental Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on November 20, 2014